{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fulvestrant&page=19", "query": { "intervention": "fulvestrant", "page": 19 }, "page_size": 10 }, "pagination": { "page": 19, "page_size": 10, "total_count": 294, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fulvestrant&page=20&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fulvestrant&page=18&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T22:12:13.936Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03643510", "title": "Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adenocarcinoma of Endometrium" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 27, "start_date": "2018-08-21", "completion_date": "2026-03-12", "has_results": true, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03643510" }, { "nct_id": "NCT05573126", "title": "Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone Receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "EP0062", "type": "DRUG" }, { "name": "Elacestrant", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ellipses Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 95, "start_date": "2023-01-11", "completion_date": "2028-02", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 7, "location_summary": "New Haven, Connecticut • Tampa, Florida • Boston, Massachusetts + 4 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT05573126" }, { "nct_id": "NCT05025735", "title": "Alpelisib, Fulvestrant and Dapagliflozin for the Treatment of HR+, HER2 -, PIK3CA Mutant Metastatic Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "HER2-negative Breast Cancer" ], "interventions": [ { "name": "Dapagliflozin 10Mg Tab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Saint Luke's Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "2021-08-25", "completion_date": "2023-07", "has_results": false, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 1, "location_summary": "Kansas City, Missouri", "locations": [ { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05025735" }, { "nct_id": "NCT05306340", "title": "A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer" ], "interventions": [ { "name": "Giredestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "Dexamethasone Mouth Rinse", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 373, "start_date": "2022-08-03", "completion_date": "2026-10-15", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 55, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 47 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05306340" }, { "nct_id": "NCT01823835", "title": "A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GDC-0810", "type": "DRUG" }, { "name": "LHRH Agonist", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 152, "start_date": "2014-12-29", "completion_date": "2020-03-13", "has_results": true, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 8, "location_summary": "San Diego, California • Boston, Massachusetts • St Louis, Missouri + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01823835" }, { "nct_id": "NCT06979596", "title": "A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Fludrocortisone/ Fludrocortisone acetate", "type": "DRUG" }, { "name": "Dexamethasone/Dexamethasone acetate", "type": "DRUG" }, { "name": "Rescue Medications", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Megestrol acetate/Medroxyprogesterone acetate", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 250, "start_date": "2025-08-11", "completion_date": "2027-11-04", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 10, "location_summary": "Anchorage, Alaska • Miami Beach, Florida • Shreveport, Louisiana + 6 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Hastings", "state": "Nebraska" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06979596" }, { "nct_id": "NCT05472792", "title": "Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Quality of Life" ], "interventions": [ { "name": "Accelerated Partial Breast Irradiation (APBI)", "type": "RADIATION" }, { "name": "tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "FEMALE", "summary": "65 Years and older · Female only" }, "enrollment_count": 90, "start_date": "2022-05-17", "completion_date": "2032-04-15", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05472792" }, { "nct_id": "NCT03633331", "title": "Testing the Effects of Palbociclib and Fulvestrant or Letrozole for Patients 70 Years of Age of Older With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor-positive Breast Cancer", "HER2/Neu Negative", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "70 Years", "maximum_age": null, "sex": "ALL", "summary": "70 Years and older" }, "enrollment_count": 93, "start_date": "2018-08-15", "completion_date": "2026-02-27", "has_results": true, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 447, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Arroyo Grande, California + 303 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03633331" }, { "nct_id": "NCT05768139", "title": "First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors, Adult" ], "interventions": [ { "name": "STX-478", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Imlunestrant", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 880, "start_date": "2023-04-17", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 28, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Lake Mary", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05768139" }, { "nct_id": "NCT05966584", "title": "A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Benralizumab", "type": "DRUG" }, { "name": "fulvestrant or AIs) and PI3K inhibition (alpelisib)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2023-07-06", "completion_date": "2024-08-02", "has_results": true, "last_update_posted_date": "2024-08-29", "last_synced_at": "2026-10-27T22:12:13.936Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05966584" } ] }